{"id":806013,"date":"2026-04-30T20:13:01","date_gmt":"2026-04-30T20:13:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=806013"},"modified":"2026-04-30T20:13:01","modified_gmt":"2026-04-30T20:13:01","slug":"pancreatic-cancer-pipeline-enters-a-new-era-of-precision-oncology-with-200-therapies-and-170-companies-advancing-nextgeneration-treatments-finds-delveinsight-alligator-bioscience-chipscreen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-enters-a-new-era-of-precision-oncology-with-200-therapies-and-170-companies-advancing-nextgeneration-treatments-finds-delveinsight-alligator-bioscience-chipscreen_806013.html","title":{"rendered":"Pancreatic Cancer Pipeline Enters a New Era of Precision Oncology with 200+ Therapies and 170+ Companies Advancing Next-Generation Treatments, Finds DelveInsight | Alligator Bioscience, ChipScreen"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777565641.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pancreatic Cancer Pipeline Enters a New Era of Precision Oncology with 200+ Therapies and 170+ Companies Advancing Next-Generation Treatments, Finds DelveInsight | Alligator Bioscience, ChipScreen\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777565641.jpg\" alt=\"Pancreatic Cancer Pipeline Enters a New Era of Precision Oncology with 200+ Therapies and 170+ Companies Advancing Next-Generation Treatments, Finds DelveInsight | Alligator Bioscience, ChipScreen\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Pancreatic Cancer Pipeline Insight<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">There are 170+ key companies, including Alligator Bioscience, ChipScreen Biosciences, Revolution Medicines, Marker Therapeutics, NanoPharmaceuticals, Beijing Biotech, and others, developing therapies for pancreatic cancer, with TQB2868 and Trabedersen among the most advanced candidates in Phase III and Phase II\/III clinical stages.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Pancreatic Cancer &ndash; Pipeline Insight<\/strong>, 2026&#8243; report provides comprehensive insights about 170+ companies developing over 200 pipeline drugs in the pancreatic cancer pipeline landscape. It covers the pancreatic cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><em>Explore the latest breakthroughs in the Pancreatic Cancer treatment landscape. Learn more about the evolving pancreatic cancer pipeline today @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Pancreatic Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In March 2026, Revolution Medicines announced nine oral and poster presentations highlighting <strong>advances across its RAS(ON) inhibitor pipeline, including daraxonrasib, at the 2026 American Association for Cancer Research (AACR) Annual Meeting.<\/strong><\/p>\n<\/li>\n<li>\n<p>In February 2026, the <strong>FDA approved OPTUNE Pax<\/strong> for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.<\/p>\n<\/li>\n<li>\n<p>In January 2026, <strong>ChipScreen Biosciences received regulatory approval<\/strong> from China&rsquo;s National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer.<\/p>\n<\/li>\n<li>\n<p>In October 2025, the U.S. <strong>FDA granted Orphan Drug Designation to daraxonrasib<\/strong> for the treatment of pancreatic cancer.<\/p>\n<\/li>\n<li>\n<p>Pancreatic cancer remains an aggressive malignancy with a five-year survival rate of approximately 13%.<\/p>\n<\/li>\n<li>\n<p>The pipeline features a robust clinical development space with 170+ active players advancing over 200 pipeline therapies across multiple stages, from discovery through Phase III.<\/p>\n<\/li>\n<li>\n<p>Key areas of focus include dual-target immunotherapies, antibody-drug conjugates (ADCs), and cell-based treatments aiming to overcome the protective tumor microenvironment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Download for updates and the latest revolution in pancreatic cancer care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Pancreatic Cancer Market Insight, Epidemiology And Market Forecast<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>TQB2868: Phase III Development<\/strong><\/p>\n<p style=\"text-align: justify;\">TQB2868 is a novel PD-1\/TGF-&beta; bifunctional fusion protein designed to simultaneously inhibit immune checkpoint pathways and modulate the tumor microenvironment. By targeting both PD-1\/PD-L1 signaling and TGF-&beta; activity, the therapy aims to enhance anti-tumor immune responses and overcome immune suppression. The drug is currently in Phase III clinical development, positioning it as one of the most advanced candidates in the pipeline.<\/p>\n<p style=\"text-align: justify;\"><strong>Trabedersen (OT-101): Phase II\/III Development<\/strong><\/p>\n<p style=\"text-align: justify;\">Trabedersen is an antisense oligodeoxynucleotide targeting TGF-&beta;2 mRNA, effectively reducing its expression and restoring immune system activity against tumor cells. Clinical studies have demonstrated encouraging safety profiles and long-term disease control in patients with pancreatic cancer. It is currently being evaluated in Phase II\/III trials as a potential targeted therapy for advanced cases.<\/p>\n<p style=\"text-align: justify;\"><strong>Antroquinonol: Small Molecule Ras Inhibitor<\/strong><\/p>\n<p style=\"text-align: justify;\">Antroquinonol is a novel small molecule that inhibits Ras signaling pathways, leading to autophagy-induced cancer cell death. Its oral administration provides a convenient therapeutic option, and its Orphan Drug Designation from the FDA underscores its potential in addressing significant unmet needs in pancreatic cancer. Currently, Antroquinonol is in Phase II clinical evaluation.<\/p>\n<p style=\"text-align: justify;\"><em>For more information on the Pancreatic Cancer Emerging Drugs Profile, download <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">DelveInsight&#8217;s comprehensive Pancreatic Cancer Pipeline Insight report<\/a>.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>The Pancreatic Cancer Pipeline Report Provides<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Detailed insights about 170+ companies developing therapies for pancreatic cancer, with aggregate therapies developed by each company.<\/p>\n<\/li>\n<li>\n<p>Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for treatment.<\/p>\n<\/li>\n<li>\n<p>Pancreatic cancer companies that are involved in targeted therapeutics development with respective active and inactive projects.<\/p>\n<\/li>\n<li>\n<p>Drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations, licensing agreements, and regulatory designations granted to new therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Learn more about pancreatic cancer drug opportunities in our comprehensive pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Pancreatic Cancer Unmet Needs<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Companies and Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">There are 170+ key companies, including Alligator Bioscience, ChipScreen Biosciences, Revolution Medicines, Marker Therapeutics, NanoPharmaceuticals, Beijing Biotech, and others, developing therapies for pancreatic cancer, with TQB2868 and Trabedersen among the most advanced candidates in Phase III and Phase II\/III clinical stages.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s pancreatic cancer pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intra-articular<\/p>\n<\/li>\n<li>\n<p>Intraocular<\/p>\n<\/li>\n<li>\n<p>Intrathecal<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Ophthalmic<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer products have been categorized under various Molecule types such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oligonucleotide<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Discover the latest advancements in pancreatic cancer treatment by visiting our website. Stay informed @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Pancreatic Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Coverage: Global<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Companies: Alligator Bioscience, ChipScreen Biosciences, Revolution Medicines, Marker Therapeutics, NanoPharmaceuticals, and others.<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Therapies: TQB2868, Trabedersen, Antroquinonol, Nadunolimab, MT-601, and others.<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer: Overview<\/p>\n<\/li>\n<li>\n<p>Pipeline Therapeutics<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer &ndash; DelveInsight&#8217;s Analytical Perspective<\/p>\n<\/li>\n<li>\n<p>Late Stage Products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid Stage Products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early Stage Products (Phase I)<\/p>\n<\/li>\n<li>\n<p>Preclinical and Discovery Stage Products<\/p>\n<\/li>\n<li>\n<p>Inactive Products<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Key Companies<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Key Products<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Market Drivers and Barriers<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Future Perspectives and Conclusion<\/p>\n<\/li>\n<li>\n<p>Pancreatic Cancer Analyst Views<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Arpit Anand<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pancreatic-cancer-pipeline-enters-a-new-era-of-precision-oncology-with-200-therapies-and-170-companies-advancing-nextgeneration-treatments-finds-delveinsight-alligator-bioscience-chipscreen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pancreatic-cancer-pipeline-enters-a-new-era-of-precision-oncology-with-200-therapies-and-170-companies-advancing-nextgeneration-treatments-finds-delveinsight-alligator-bioscience-chipscreen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pancreatic Cancer Pipeline Insight There are 170+ key companies, including Alligator Bioscience, ChipScreen Biosciences, Revolution Medicines, Marker Therapeutics, NanoPharmaceuticals, Beijing Biotech, and others, developing therapies for pancreatic cancer, with TQB2868 and Trabedersen among the most advanced candidates in Phase III &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-enters-a-new-era-of-precision-oncology-with-200-therapies-and-170-companies-advancing-nextgeneration-treatments-finds-delveinsight-alligator-bioscience-chipscreen_806013.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-806013","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=806013"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=806013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=806013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=806013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}